Mid-Afternoon Market Update: Dow Falls 275 Points; BeyondSpring Shares Spike Higher
Toward the end of trading Wednesday, the Dow traded down 0.78% to 34,841.21 while the NASDAQ rose 0.29% to 14,803.80. The S&P also fell, dropping 0.26% to 4,411.84.
Needham Maintains Buy on Cardlytics, Lowers Price Target to $120
Needham analyst Kyle Peterson maintains Cardlytics (NASDAQ:CDLX) with a Buy and lowers the price target from $135 to $120.
14 Stocks Moving In Tuesday’s After-Hours Session
RingCentral (NYSE: RNG) shares are trading higher after the company reported better-than-expected Q2 EPS and sales results and issued Q3 and FY21 EPS and sales guidance above estimates.
Cardlytics Q2 Adj. EPS $(0.39), Inline, Sales $58.90M Miss $62.81M Estimate; Sees Q3 Sales $57M-$66M vs $71M Estimate, Billings $85M-$95M
Cardlytics (NASDAQ:CDLX) reported quarterly losses of $(0.39) per share which met the analyst consensus estimate. This is a 2.63 percent decrease over losses of $(0.38) per share from the same period last year. The
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.
Needham Initiates Coverage On Cardlytics with Buy Rating, Announces Price Target of $135
Needham analyst Kyle Peterson initiates coverage on Cardlytics (NASDAQ:CDLX) with a Buy rating and announces Price Target of $135.